Optimization and evaluation of novel tetrahydropyrido[4,3-d]pyrimidine derivatives as ATX inhibitors for cardiac and hepatic fibrosis.
Optimization and evaluation of novel tetrahydropyrido[4,3-d]pyrimidine derivatives as ATX inhibitors for cardiac and hepatic fibrosis.
复制标题
DOI:
10.1016/j.ejmech.2019.111904
复制
发表时间:
2019-11
影响因子:
6.7
通讯作者:
Nan Jiang;Yuhong Zhou;Minglin Zhu;Junlong Zhang;Meng Cao;Hongrui Lei;Ming-juan Guo;P. Gong-
中科院分区:
文献类型:
--
作者:
Nan Jiang;Yuhong Zhou;Minglin Zhu;Junlong Zhang;Meng Cao;Hongrui Lei;Ming-juan Guo;P. Gong-
Aiming to develop potent autotaxin (ATX) inhibitors for fibrosis diseases, a novel series of tetrahydropyrido[4,3-d]pyrimidine derivatives was designed and synthesized based on our previous study. The enzymatic assay combined with anti-proliferative activities against cardiac fibroblasts (CFs) and hepatic stellate cell (HSC)in vitrowere applied for preliminary evaluation of anti-fibrosis potency of target compounds, resulting in two outstanding ATX inhibitors8band10gwith the IC50values in a nanomolar range (24.6 and 15.3 nM). Differently,8bwas the most prominent compound against CFs with inhibition ratio of 81.5%, while10gexhibited the maximum inhibition ratio of 83.7% against t-HSC/Cl-6 cells. In the further pharmacological evaluationsin vivo, collagen deposition assay demonstrated the conspicuous capacity of8bto suppress TGF-β-mediated cardiac fibrosis. Simultaneously, H&E and Masson stains assays of mice liver validated10gas an excellent anti-hepatofibrosis candidate, which reduced CCl4-induced hepatic fibrosis level prominently. Besides, the molecular binding models identified the essential interactions between8band ATX which was coincided with the SARs.